from the Fall 2009 issue
Dysport® is a new botulinum toxin type A that was approved by the FDA in April 2009 to treat moderate to severe globular (frown) lines in adult patients less than 65 years of age. It is sold in the U.S. by Medicis, the company that sells the dermal filler, Restylane.
To distinguish it from the first FDA-approved botulinum toxin type A (BOTOX® Cosmetic), the generic name for Dysport® is now abobotulinumtoxin A. Dysport® was first licensed for medical use in 1990 in Europe. Just like BOTOX®, Dysport® has numerous medical uses in neurology, rehabilitation medicine and ophthalmology. Although Dysport® cosmetically is only FDA-approved to treat the frown lines between the eyebrows, we can and do use it to treat other areas prone to wrinkles, such as the horizontal forehead lines and crow’s feet.
Even though BOTOX® Cosmetic and Dysport® are both botulinum toxin type A, there are technical and clinical differences between the two products. The main difference is the different dosing that is used in the two products. To achieve the same effect, we use approximately two to three units of Dysport® for every one unit of BOTOX® Cosmetic. Still, the cost of a Dysport® treatment is about the same as that of BOTOX® Cosmetic. From the clinical trials on Dysport®, the duration of the effect was a median of 117 days, roughly the same as BOTOX® Cosmetic.
Since Dysport® is so new in the U.S., we will have to use it a while to get a feel for how it compares to our old standby. From our experience and the evidence we’ve seen presented so far, it appears to be another great option for treating wrinkles.
To see if this new wrinkle relaxer is right for you, call 713.850.0240 and schedule your consultation appointment.
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |